{"title":"转移性NSCLC患者靶向治疗模式的更新。","authors":"Narjust Florez Duma, Stephanie Mcdonald","doi":"10.6004/jadpro.2023.14.3.12","DOIUrl":null,"url":null,"abstract":"<p><p>The treatment paradigm for metastatic non-small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from recent clinical trials of biomarkers and their respective targeted therapies, and best practices for monitoring and managing side effects associated with targeted therapies for metastatic non-small cell lung cancer.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"241-247"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/4f/jadpro-14-241.PMC10184836.pdf","citationCount":"0","resultStr":"{\"title\":\"Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC.\",\"authors\":\"Narjust Florez Duma, Stephanie Mcdonald\",\"doi\":\"10.6004/jadpro.2023.14.3.12\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The treatment paradigm for metastatic non-small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from recent clinical trials of biomarkers and their respective targeted therapies, and best practices for monitoring and managing side effects associated with targeted therapies for metastatic non-small cell lung cancer.</p>\",\"PeriodicalId\":17176,\"journal\":{\"name\":\"Journal of the Advanced Practitioner in Oncology\",\"volume\":\"14 3\",\"pages\":\"241-247\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/4f/jadpro-14-241.PMC10184836.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Advanced Practitioner in Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2023.14.3.12\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Advanced Practitioner in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2023.14.3.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
自靶向治疗出现以来，转移性非小细胞肺癌的治疗模式发生了显著变化。在JADPRO Live 2022期间，演讲者重点介绍了临床实践指南的重要更新，生物标志物及其各自靶向治疗的最新临床试验数据，以及监测和管理转移性非小细胞肺癌靶向治疗相关副作用的最佳实践。
Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC.
The treatment paradigm for metastatic non-small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from recent clinical trials of biomarkers and their respective targeted therapies, and best practices for monitoring and managing side effects associated with targeted therapies for metastatic non-small cell lung cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
